Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to -$275000.0.

  • Exagen's Cash from Investing Activities fell 8707.48% to -$275000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$737000.0, marking a year-over-year decrease of 6269.32%. This contributed to the annual value of -$515000.0 for FY2024, which is 3594.53% up from last year.
  • Per Exagen's latest filing, its Cash from Investing Activities stood at -$275000.0 for Q3 2025, which was down 8707.48% from -$209000.0 recorded in Q2 2025.
  • In the past 5 years, Exagen's Cash from Investing Activities registered a high of -$2000.0 during Q3 2023, and its lowest value of -$1.9 million during Q2 2022.
  • For the 5-year period, Exagen's Cash from Investing Activities averaged around -$455157.9, with its median value being -$275000.0 (2025).
  • In the last 5 years, Exagen's Cash from Investing Activities tumbled by 2118000.0% in 2021 and then soared by 9977.25% in 2023.
  • Quarter analysis of 5 years shows Exagen's Cash from Investing Activities stood at -$1.1 million in 2021, then surged by 61.84% to -$406000.0 in 2022, then skyrocketed by 79.31% to -$84000.0 in 2023, then tumbled by 73.81% to -$146000.0 in 2024, then crashed by 88.36% to -$275000.0 in 2025.
  • Its Cash from Investing Activities was -$275000.0 in Q3 2025, compared to -$209000.0 in Q2 2025 and -$107000.0 in Q1 2025.